Article
Pharmacology & Pharmacy
Xiao Guan, Dan Yu, Mengjie HuangFu, Zhiyi Huang, Tong Dou, Yisa Liu, Luwei Zhou, Xumei Li, Lin Wang, Haiping Liu, Juan Wang, Xu Chen
Summary: The study demonstrated that curcumol inhibits invasion and metastasis of EBV-positive NPC cells by targeting NCL, which further regulates related signaling pathways, providing a new pharmacological basis for clinical treatment.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Ioanna Liatsou, Anders Josefsson, Jing Yu, Zhi Li, Kaori Davis, Cory Brayton, Hao Wang, Robert F. Hobbs, George Sgouros
Summary: The purpose of this study was to determine the dose-independent RBE2 of bone marrow for an alpha-particle emitter RPT. The results showed that the dose-independent RBE2 for bone marrow was 6. This is important for understanding the differences between aRPT and beta-particle emitter RPT.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Pharmacology & Pharmacy
Adhika Balgobind, Aliscia Daniels, Mario Ariatti, Moganavelli Singh
Summary: This study assessed the efficacy of cationic lipid-based systems for the delivery of HER2/neu siRNA in breast cancer. The results showed that cationic liposomes efficiently bound, compacted, and protected the therapeutic siRNA against degradation. The non-PEGylated Chol-T-siRNA lipoplexes exhibited the highest HER2/neu silencing.
Article
Oncology
Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Summary: Companion diagnostic test for trastuzumab has remained largely unchanged over the last 25 years. High-plex digital spatial profiling identified alpha-smooth muscle actin (alpha-SMA) as a potential biomarker of resistance to trastuzumab in HER2-positive breast cancer. Orthogonal validation confirmed the association of high alpha-SMA expression with shorter disease-free survival, suggesting its potential role in predicting response to trastuzumab in combination therapy settings.
CLINICAL CANCER RESEARCH
(2021)
Article
Microbiology
Danijela Miljanovic, Andja Cirkovic, Ivica Jermic, Milica Basaric, Ivana Lazarevic, Milka Grk, Rada Miskovic, Aleksa Despotovic, Ana Banko
Summary: The study aimed to analyze the association between EBV and RA by examining antibody titers, DNA viremia, infection status and EBNA1 variants in RA patients. The results showed a higher prevalence of active/recent EBV infection in RA patients compared to controls, along with elevated levels of specific antibodies. The findings suggest the need for further research to understand the causal relationship between EBV and RA. Evaluation: 8/10.
Article
Oncology
Jianguo Lai, Bo Chen, Yingzi Li, Xiaoyi Lin, Min Li, Jing Liu, Ning Liao
Summary: This study identified five key cell cycle-related genes (CDK4, CCND1, CDKN1A, CDKN1C, and CHEK2) as independent prognostic variables in HR+/HER2- BC patients. A risk score based on these five genes effectively classified patients into low-risk and high-risk groups. The potential functional pathways of these genes include cell cycle regulation and G1/S transition.
Article
Oncology
Catherine S. Forconi, David H. Mulama, Priya Saikumar Lakshmi, Joslyn Foley, Juliana A. Otieno, Jonathan D. Kurtis, Leslie J. Berg, John M. Ong'echa, Christian Muenz, Ann M. Moormann
Summary: Children diagnosed with endemic Burkitt lymphoma (eBL) show deficient IFN-? responses to EBNA1, but the specific contributions of immune-regulatory cytokines and EBNA1-specific T cell phenotypes have not been clearly characterized. Our study compared cytokine expression and T cell memory profiles in response to EBNA1 and a malaria antigen among eBL patients and healthy children with different malaria exposures. Results indicate that eBL children have lower rates of EBNA1-specific IFN-? producing CD4(+) T cells compared to healthy children with high or low malaria exposures.
Review
Oncology
Martina Di Modica, Valeria Arlotta, Lucia Sfondrini, Elda Tagliabue, Tiziana Triulzi
Summary: Microbiota plays a key role in cancer by influencing various host physiological functions and affecting the efficacy of anticancer treatments. The involvement of the breast microbiota in breast cancer has been extensively studied. This review focuses on the impact of gut and breast microbiota on HER2+ breast cancer subtype and discusses the potential of defining microbial signatures associated with disease aggressiveness, treatment response, and therapy toxicity. The mechanisms of microorganism-host interactions and the possibility of microbiota editing in breast cancer prevention and treatment optimization are also explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Jayaraju Dheekollu, Andreas Wiedmer, Kasirajan Ayyanathan, Julianna S. Deakyne, Troy E. Messick, Paul M. Lieberman
Summary: This study reveals that EBNA1 forms cell cycle-dependent DNA crosslinks with the EBV origin of plasmid replication and the tyrosine 518 residue is essential for this process. These crosslinks and single-strand cleavage are critical for replication termination and viral episome maintenance.
Article
Immunology
Ana Banko, Andja Cirkovic, Rada Miskovic, Ivica Jeremic, Milka Grk, Milica Basaric, Ivana Lazarevic, Sanvila Raskovic, Aleksa Despotovic, Danijela Miljanovic
Summary: The study found that there is a significant association between EBV infection and SLE development. Anti-EBV-EA(D) IgG antibodies were shown to increase the possibility of having SLE by 24 times in SLE patients. Higher titers of anti-EBV-EA(D) IgG antibodies were associated with lymphopenia and hematological SLE manifestation. Furthermore, novel data on EBV EBNA1 and LMP1 gene polymorphisms in lupus were reported.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Genetics & Heredity
Yue Liang, Wen Liu, Menghe Zhao, Duo Shi, Yan Zhang, Bing Luo
Summary: This study aimed to investigate the association of Epstein-Barr virus (EBV) with nuclear respiratory factor 1 (NRF1) and its biological function in EBV-associated gastric cancer (EBVaGC). It was found that LMP2A upregulated NRF1 expression by activating the NF-kappa B pathway and promoted cell migration and the anti-apoptotic ability of cells. NRF1 also maintained latent infection of EBV by regulating the expression of specific proteins. These findings provide a new theoretical basis for NRF1-based anti-cancer therapy.
Article
Biochemistry & Molecular Biology
Sudath Hapuarachchige, Ge Si, Colin T. Huang, Wojciech G. Lesniak, Ronnie C. Mease, Xin Guo, Kathleen Gabrielson, Dmitri Artemov
Summary: Pretargeted drug delivery using a HER2 pretargeting component and a drug delivery component showed significant therapeutic efficacy in a HER2-positive breast cancer model, demonstrating a promising approach for cancer therapy.
Article
Biology
Nannan Duan, Shuqing Tang, Baitao Zeng, Zhiqing Hu, Qian Hu, Lingqian Wu, Miaojin Zhou, Desheng Liang
Summary: A novel gene editing system named COE was developed, achieving up to 90% insertion or deletion rates in HEK-293T cells and high editing efficiency in iPSCs. Additionally, Exon 51-deleted iPSCs derived from cardiomyocytes exhibited similar expression profiles to patient-specific iPSCs for Duchenne muscular dystrophy (DMD).
Article
Biology
Ioanna Liatsou, Jing Yu, Remco Bastiaannet, Zhi Li, Robert F. Hobbs, Julien Torgue, George Sgouros
Summary: The RBE of a Pb-212-conjugated anti-HER2/neu antibody construct was evaluated in this study using a colony formation assay. The results showed that the radiolabeled antibody had a high RBE at 37% survival, and the unbound antibody had minimal radiation to cells.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2022)
Review
Immunology
Xinle Cui, Clifford M. Snapper
Summary: EBV is strongly implicated in the etiology of multiple cancers, and vaccines targeting EBV have shown promise in prevention and treatment. Immune cell therapy, including adoptive T-cell therapy, has emerged as a promising approach in cancer treatment, especially in EBV-associated cancers.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.